Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises
Ovarian cancer is the deadliest gynecological cancer, the high-grade serous ovarian carcinoma (HGSC) being its most common and most aggressive form. Despite the latest therapeutical advancements following the introduction of vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6257 |
| _version_ | 1797461003285299200 |
|---|---|
| author | Aikaterini Skorda Marie Lund Bay Sampsa Hautaniemi Alexandra Lahtinen Tuula Kallunki |
| author_facet | Aikaterini Skorda Marie Lund Bay Sampsa Hautaniemi Alexandra Lahtinen Tuula Kallunki |
| author_sort | Aikaterini Skorda |
| collection | DOAJ |
| description | Ovarian cancer is the deadliest gynecological cancer, the high-grade serous ovarian carcinoma (HGSC) being its most common and most aggressive form. Despite the latest therapeutical advancements following the introduction of vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors and poly-ADP-ribose-polymerase (PARP) inhibitors to supplement the standard platinum- and taxane-based chemotherapy, the expected overall survival of HGSC patients has not improved significantly from the five-year rate of 42%. This calls for the development and testing of more efficient treatment options. Many oncogenic kinase-signaling pathways are dysregulated in HGSC. Since small-molecule kinase inhibitors have revolutionized the treatment of many solid cancers due to the generality of the increased activation of protein kinases in carcinomas, it is reasonable to evaluate their potential against HGSC. Here, we present the latest concluded and on-going clinical trials on kinase inhibitors in HGSC, as well as the recent work concerning ovarian cancer patient organoids and xenograft models. We discuss the potential of kinase inhibitors as personalized treatments, which would require comprehensive assessment of the biological mechanisms underlying tumor spread and chemoresistance in individual patients, and their connection to tumor genome and transcriptome to establish identifiable subgroups of patients who are most likely to benefit from a given therapy. |
| first_indexed | 2024-03-09T17:14:12Z |
| format | Article |
| id | doaj.art-3e1297381ab4482983c7b87f80a3f25d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:14:12Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3e1297381ab4482983c7b87f80a3f25d2023-11-24T13:48:59ZengMDPI AGCancers2072-66942022-12-011424625710.3390/cancers14246257Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future PromisesAikaterini Skorda0Marie Lund Bay1Sampsa Hautaniemi2Alexandra Lahtinen3Tuula Kallunki4Cancer Invasion and Resistance Group, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, DenmarkCancer Invasion and Resistance Group, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, DenmarkResearch Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, FI-00014 Helsinki, FinlandResearch Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, FI-00014 Helsinki, FinlandCancer Invasion and Resistance Group, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, DenmarkOvarian cancer is the deadliest gynecological cancer, the high-grade serous ovarian carcinoma (HGSC) being its most common and most aggressive form. Despite the latest therapeutical advancements following the introduction of vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors and poly-ADP-ribose-polymerase (PARP) inhibitors to supplement the standard platinum- and taxane-based chemotherapy, the expected overall survival of HGSC patients has not improved significantly from the five-year rate of 42%. This calls for the development and testing of more efficient treatment options. Many oncogenic kinase-signaling pathways are dysregulated in HGSC. Since small-molecule kinase inhibitors have revolutionized the treatment of many solid cancers due to the generality of the increased activation of protein kinases in carcinomas, it is reasonable to evaluate their potential against HGSC. Here, we present the latest concluded and on-going clinical trials on kinase inhibitors in HGSC, as well as the recent work concerning ovarian cancer patient organoids and xenograft models. We discuss the potential of kinase inhibitors as personalized treatments, which would require comprehensive assessment of the biological mechanisms underlying tumor spread and chemoresistance in individual patients, and their connection to tumor genome and transcriptome to establish identifiable subgroups of patients who are most likely to benefit from a given therapy.https://www.mdpi.com/2072-6694/14/24/6257clinical trialshigh-grade serous ovarian carcinomakinase inhibitorpatient-derived tumor organoidspatient-derived xenograftspersonalized medicine |
| spellingShingle | Aikaterini Skorda Marie Lund Bay Sampsa Hautaniemi Alexandra Lahtinen Tuula Kallunki Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises Cancers clinical trials high-grade serous ovarian carcinoma kinase inhibitor patient-derived tumor organoids patient-derived xenografts personalized medicine |
| title | Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises |
| title_full | Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises |
| title_fullStr | Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises |
| title_full_unstemmed | Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises |
| title_short | Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises |
| title_sort | kinase inhibitors in the treatment of ovarian cancer current state and future promises |
| topic | clinical trials high-grade serous ovarian carcinoma kinase inhibitor patient-derived tumor organoids patient-derived xenografts personalized medicine |
| url | https://www.mdpi.com/2072-6694/14/24/6257 |
| work_keys_str_mv | AT aikateriniskorda kinaseinhibitorsinthetreatmentofovariancancercurrentstateandfuturepromises AT marielundbay kinaseinhibitorsinthetreatmentofovariancancercurrentstateandfuturepromises AT sampsahautaniemi kinaseinhibitorsinthetreatmentofovariancancercurrentstateandfuturepromises AT alexandralahtinen kinaseinhibitorsinthetreatmentofovariancancercurrentstateandfuturepromises AT tuulakallunki kinaseinhibitorsinthetreatmentofovariancancercurrentstateandfuturepromises |